Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06406660
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 109
- Registration Number
- NCT06394661
- Locations
- 🇨🇳
Henan cacer hospital, Henan, Henan, China
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06370416
- Locations
- 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06335147
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06334757
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06329973
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 224
- Registration Number
- NCT06293014
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06285149
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 71
- Registration Number
- NCT06276868
- Locations
- 🇨🇳
Henan cacer hospital, Henan, Henan, China
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
Not yet recruiting
- Conditions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 288
- Registration Number
- NCT06267170
© Copyright 2024. All Rights Reserved by MedPath